Abstract
Late-onset toxicity is common for immunotherapies and targeted therapies. It causes major logistic difficulty in conducting phase I trials using most existing phase I designs, which require that toxicity can be observed quickly to inform the dose assignment for the next new cohort of patients. This chapter introduces three model-based designs, including the time-to-event CRM (TITE-CRM), fractional CRM (fCRM), data augmentation CRM (DA-CRM), and a model-assisted design, i.e., time-to-event BOIN (TITE-BOIN), to deal with late-onset toxicity. Trial examples and software are provided to demonstrate the implementation of designs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Atrash, G. (2018). Nivolumab and Ipilimumab after donor stem cell transplant in treating participants with high risk refractory or relapsed acute myeloid leukemia. ClinicalTrials. gov Identifier: NCT03600155.
Babb, J., Rogatko, A., & Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine, 17(10), 1103–1120.
Chan, C. Y., Li, H., Wu, M. F., Liu, C. H., Lu, H. W., Lin, Z. Q., & Li, J. (2021). A dose-finding trial for hyperthermic intraperitoneal cisplatin in gynecological cancer patients receiving hyperthermic intraperitoneal chemotherapy. Frontiers in Oncology, 11, 672.
Cheung, Y. K., & Chappell, R. (2000). Sequential designs for phase I clinical trials with lateonset toxicities. Biometrics, 56(4), 1177–1182.
Efron, B. (1967, January). The two sample problem with censored data. In Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability (Vol. 4, pp. 831–853). University of California Press.
Furman, R. R., Martin, P., Ruan, J., Cheung, Y. K. K., Vose, J. M., LaCasce, A. S., Elstrom, R., Coleman, M., & Leonard, J. P. (2010). Phase 1 trial of bortezomib plus RCHOP in previously untreated patients with aggressive nonHodgkin lymphoma. Cancer, 116(23), 5432–5439.
Guirgis, F. W., Black, L. P., DeVos, E., Henson, M., Ferreira, J., Miller, T., Rosenthal, M., Leeuwenburgh, C., Kalynych, C., Moldawer, L., & Moore, F. (2020). Lipid intensive drug therapy for sepsis pilot: A Bayesian phase I clinical trial. Journal of the American College of Emergency Physicians Open, 1(6), 1332–1340.
Huang, B., & Kuan, P. F. (2014). Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial. Biometrical Journal, 56(6), 933–946.
Ivanova, A., Flournoy, N., & Chung, Y. (2007). Cumulative cohort design for dose-finding. Journal of Statistical Planning and Inference, 137(7), 2316–2327.
Leonard, J. P., Abramson, J. S., & Rutherford, S. (2017). Study of Venetoclax Plus DA-EPOCH-R for the treatment of aggressive B-cell lymphomas (V+ DA-EPOCH-R). ClinicalTrials. gov Identifier: NCT03036904.
Lin, R., & Yuan, Y. (2020). Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics, 21(4), 807–824.
Little, R. J., & Rubin, D. B. (2019). Statistical analysis with missing data (Vol. 793). John Wiley & Sons.
Liu, S., Yin, G., & Yuan, Y. (2013). Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. The Annals of Applied Statistics, 7(4), 1837.
Magenau, J., Tobai, H., Pawarode, A., Braun, T., Peres, E., Reddy, P., Kitko, C., Choi, S., Yanik, G., Frame, D., & Mineishi, S. (2011). Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood, The Journal of the American Society of Hematology, 118(15), 4258-4264.
Normolle, D., & Lawrence, T. (2006). Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. Journal of Clinical Oncology, 24(27), 4426–4433.
Phan, J. (2017). Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) treatment of laryngeal cancer. ClinicalTrials.gov Identifier: NCT03114462.
Phan, T. G., Ma, H., Lim, R., Sobey, C. G., & Wallace, E. M. (2018). Phase 1 trial of amnion cell therapy for ischemic stroke. Frontiers in Neurology, 9, 198.
van Werkhoven, E., Hinsley, S., Frangou, E., Holmes, J., de Haan, R., Hawkins, M., Brown, S., & Love, S. B. (2020). Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples. BMC Medical Research Methodology, 20(1), 1–10.
Wu, C., Liu, C., Zhu, Y., Zhou, Z., Jiang, T., Liu, W., Li, H., Wu, C., & Ye, B. (2016). Early Paleozoic magmatic history of central Inner Mongolia, China: implications for the tectonic evolution of the Southeast Central Asian Orogenic Belt. International Journal of Earth Sciences, 105(5), 1307–1327.
Yin, G., & Yang, Z. (2020). Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies. Contemporary Clinical Trials Communications, 100650.
Yuan, Y., Wu, J., & Gilbert, M. R. (2021). BOIN: A novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neuro-Oncology Practice.
Yuan, Y., Lin, R., Li, D., Nie, L., & Warren, K. E. (2018). Time-to-event Bayesian optimal interval design to accelerate phase I trials. Clinical Cancer Research, 24(20), 4921–4930.
Zhao, Lili, Lee, Julia, Mody, Rajen, & Braun, Thomas M. (2011). The superiority of the time-to-event continual reassessment method to the rolling six design in pediatric oncology Phase I trials. Clinical Trials, 8(4), 361–369.
Zhou, H., Chen, C., Sun, L., & Zeng, Z. (2021). A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities. Contemporary Clinical Trials, 105, 106404.
Zhou, T., Guo, W., & Ji, Y. (2020). Pod-tpi: Probability-of-decision toxicity probability interval design to accelerate phase I trials. Statistics in Biosciences, 12(2), 124–145.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2023 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Pan, H., Yuan, Y. (2023). Phase I Designs for Late-Onset Toxicity. In: Bayesian Adaptive Design for Immunotherapy and Targeted Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-19-8176-0_2
Download citation
DOI: https://doi.org/10.1007/978-981-19-8176-0_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-8174-6
Online ISBN: 978-981-19-8176-0
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)